OR WAIT null SECS
March 06, 2026
Video
Maddox discusses the AHA’s recent statement indicating that, should current trends continue, 6 in 10 US women will have cardiovascular disease by 2050.
March 02, 2026
Article
Catch up with FDA decisions, key trial results, and more.
February 06, 2026
Ruff explains his prespecified analysis of the phase 2b AZALEA-TIMI 71 trial, highlighting abelacimab’s efficacy and durability compared to rivaroxaban.
January 29, 2026
Milestone Pharmaceuticals’ novel, self-administered medication for paroxysmal supraventricular tachycardia has released alongside a patient support program.
January 13, 2026
The KAI 12L program is now cleared to determine short PR interval, atrial bigeminy, ventricular bigeminy, left axis deviation, and right axis deviation.
December 13, 2025
The FDA has approved etripamil nasal spray for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm.
December 04, 2025
Catch up with major FDA decisions, critical conference news, and more.
December 03, 2025
Gibson discusses the promising improvements to the composite primary endpoint of mortality, stroke, and recurrent MI as a result of zalunfiban treatment.
November 09, 2025
Data from the DECAF study suggests caffeine may have a slightly beneficial effect on AF recurrence, although investigators urge caution in interpretation.
September 03, 2025
A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.
